Last week, the US Food and Drug Administration (FDA) approved the world's first vaccine against the chikungunya virus – Ixchiq. The vaccine candidate has been designed and manufactured at the University of Tartu. The human clinical trials were conducted by the biotechnology company Valneva Austria GmbH.
At the International Sport and Culture Association’s annual MOVE congress on 15–17 November, the Move Lab of the Institute of Sports Science and Physiotherapy, with its Schools in Motion programme, was selected as the winner in the health-promoting schools category.
The richly illustrated book on the first one hundred years of the Estonian-language university in Tartu (“Eestikeelse Tartu ülikooli esimene aastasada”) will be presented in the White Hall of the University of Tartu Museum on 28 November.